Related Experiment Videos
Evaluation of pentraxin-3 level and its related factors in patients undergoing primary percutaneous coronary
Saeed Alipour-Parsa1, Habib Haybar2, Mohammad Hasan Namazi3
1Associate Professor, Cardiovascular Research Center AND Department of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Insights
Pentraxin-3 (PTX3) levels correlate with severity in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention (PCI). Higher PTX3 indicates worse outcomes, including higher GRACE scores and lower ejection fraction.
Area of Science:
- Cardiology
- Biomarkers
- Inflammation
Background:
- Inflammation is crucial in atherosclerosis development and progression.
- Acute phase proteins like pentraxin-3 (PTX3) aid in coronary artery disease (CAD) prognosis.
- Evaluating PTX3 levels and related factors in patients undergoing primary percutaneous coronary intervention (PCI) is important.
Purpose of the Study:
- To assess pentraxin-3 (PTX3) levels in patients with ST-elevation myocardial infarction (STEMI) undergoing primary PCI.
- To identify factors related to PTX3 levels in this patient cohort.
Main Methods:
- A cross-sectional study involving 100 STEMI patients undergoing primary PCI.
- Collected demographic data, medical history, and cardiac disease characteristics.
- Measured PTX3 levels before PCI.
Main Results:
- Higher PTX3 levels were associated with increased Global Registry of Acute Coronary Events (GRACE) scores.
- Abnormal PTX3 levels correlated with the number of involved coronary vessels, MI type, and need for PCI.
- Elevated PTX3 correlated with higher Killip class, lower ejection fraction, and higher GRACE score, and different platelet counts.
Conclusions:
- PTX3 is a significant biomarker in cardiovascular diseases, with established diagnostic and prognostic value.
- Clinical signs alone can make differentiating high-risk from low-risk acute cardiac infarction patients challenging.
- PTX3 may aid in risk stratification for acute myocardial infarction patients undergoing PCI.
Background:
Inflammation has an important role in the development and progression of atherosclerosis, and acute phase proteins such as pentraxin-3 (PTX3) can be deployed in determining the prognosis of coronary artery disease (CAD). So the purpose of this paper was to evaluate the PTX3 level and its related factors in patients undergoing primary percutaneous coronary intervention (PCI).
Methods:
In this cross-sectional study, the PTX3 levels were determined for 100 patients with ST-elevation myocardial infarction referred to the Modarres Hospital, Tehran, Iran. Checklist included demographic data [age, gender, history of myocardial infarction (MI)] and characteristics of heart disease (type of MI, culprit, and pre-dilation). PTX3 was measured for all patients before PCI.
Results:
In this study, the mean age of the participants was 58.7 (11.4). Global registry of acute coronary events (GRACE) score was higher in the group with abnormal PTX3 levels (P = 0.008). The number of the involved vessels (P = 0.005), MI type (P = 0.05), and the need for PCI all had a significant relation with abnormal PTX3 levels. The increased levels of PTX3 received higher Killip class, lower ejection fraction, and higher GRACE score. The group with abnormal PTX3 had a significant difference in platelet counts (P = 0.018) in comparison with the group with normal level of PTX3.
Conclusion:
Currently, the biomarkers are highly important in the field of cardiovascular diseases. The diagnostic and prognostic importance of PTX3 as a new marker has been underscored in recent studies. Differentiating between high-risk patients with acute cardiac infarction and low-risk ones through their clinical signs is difficult.